Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Accuray Buys Some Breathing Room, But Orders Need To Materialize

Investors had already braced themselves for a bad quarter and a near-total reset of expectations at small med-tech company Accuray (NASDAQ:ARAY), and the company actually came through with a slightly better quarter. Even so, investors apparently didn't like the fact that management didn't improve its order or revenue guidance, and/or the announcement of a $100 million convertible debt offering.

I've spoken at some length regarding my frustrations with Accuray, and my continued interest (and ownership) in the stock comes down to this - Accuray has developed some radiation therapy systems that offer solid advantages over the systems sold by Varian (NYSE:VAR) and Elekta (OTCPK:EKTAY). If the company can effectively manufacture, market, and support these...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details